**CURRICULUM VITAE**



Nader Nabil Hanna, MB., BCh., FACS, FICS, FSSO

Professor of Surgery

University of Maryland School of Medicine

Director of Clinical Operations, Division of General and Oncologic Surgery, University of Maryland Medical Center

**CONTACT INFORMATION**

Business Address: University of Maryland Medical Center

29 S. Greene Street, Suite GS609C

Baltimore, MD 21201

Phone Number: (410) 328-7320

Fax Number: (410) 328-5919

E-mail: [nhanna@som.umaryland.edu](mailto:nhanna@som.umaryland.edu)

**EDUCATION**

1979-1985 M.B., B.Ch., Faculty of Medicine, Ain Shams University, Cairo, Egypt.

**POSTGRADUATE EDUCATION**

1986-1987 Rotating Internship, Ain Shams University Hospitals, Cairo, Egypt

1988-1989 Intern in Medicine/Surgery, Waltham-Weston Hospital and Medical Center, Waltham, MA

1989-1993 Resident in Surgery, PGY I - IV, Department of Surgery, St. Elisabeth’s Medical Center, Tufts University School of Medicine, Boston, MA

1993-1994 Chief Surgical Resident, Department of Surgery, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA

1994-1997 Surgical Oncology Fellowship, Department of Surgery, University of

Chicago, Pritzker School of Medicine, Chicago, IL

1997-1998 Postdoctoral Research Fellow, Division of the Biological Sciences,

Department of Radiation & Cellular Oncology, University of Chicago, Pritzker School of Medicine, Chicago, IL

**POST GRADUATE COURSES**

1995 Cryotherapy for Hepatic Tumors, University of Chicago

1996 Hepatic and Anorectal Ultrasound for the General Surgeon, University of

Chicago

1997 Ultrasound for the Surgical Oncologist “Hands-On” Lab, Society of Surgical Oncology

1999, 2002 Navigating the Clinical Research Process, Investigator Training Series, University of Kentucky

2000 Young Surgical Investigators Conference, American College of Surgeons

2000 Course in Clinical Trial Methods, American College of Surgeons

2002 Medical School Admission Interview Workshop, University of Kentucky

2007 Surgeons as Leaders: From operating room to Boardroom, American

College of Surgeon

2017 Program for Excellence in Patient-Centered Communications

2017 Train-the-Trainer Program: Relationship-Centered Communication Skills

**CERTIFICATIONS**

1987 ECFMG Certificate

1996 Board-certified general surgeon (#041243)

1997 Special certification: Surgical Oncology

2006, 2016 Re-certification in general Surgery (expiration: 12/31/2026)

**MEDICAL LICENSURES**

##### Egypt Medical License (Inactive)

State of Massachusetts (Inactive)

State of Illinois (Inactive)

State of Kentucky (Inactive)

State of Maryland (Active)

**EMPLOYMENT HISTORY**

**Academic Appointments**

1998-2004 Assistant Professor of Surgery, Department of Surgery, University of Kentucky School of Medicine, Lexington, KY

2004 Associate Professor of Surgery *(Tenured)*, Department of Surgery, University of Kentucky School of Medicine, Lexington, KY

2004-2012 Associate Professor of Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD

2012-Present Professor of Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD

**Clinical Employment**

1994-1998 Trauma Surgeon, Lutheran General Hospital, Park Ridge, IL

1998-2004 Staff Surgeon, Veterans Administration Medical Center, Cooper Drive Division, Lexington, KY

1998-2004 Member, Lucille Markey Cancer Center, Lexington, KY

2003-2004 Director, Gastrointestinal Clinical Research, Lucille Markey Cancer Center, Lexington, KY

2004-Present Member, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

2004-2009 Chief, Section of Surgical Oncology, Department of Surgery, University of Maryland Medical center, Baltimore, MD

2006-2015 Medical Director of the Surgical IMC unit, University of Maryland Medical center, Baltimore, MD

2009- 2012 Head, Division of Surgical Oncology, Department of Surgery, University of Maryland Medical center, Baltimore, MD

2012-Present Director of Clinical Operations, Division of General & Oncologic Surgery, University of Maryland Medical center, Baltimore, MD

4/2015-6/2019 Director, Cancer Institute, University of Maryland St. Joseph Medical Center

**PROFESSIONAL MEMBERSHIP**

1995-present Society of Surgical Oncology

1997-present American College of Surgeons

2000-present American Society of Clinical Oncology

2000-present Association for Academic Surgery

2003-present Leadership Society of the American College of Surgeons

2003-present International College of Surgeons

2013-present Society of University Surgeons

2017-present American Academy on Communications in Healthcare

**HONORS AND AWARDS**

1985 MB., BCh.: Very Good with Honors (equivalent to Magna Cum Laude)

1998 Chicago Surgical Society Award for Surgical Research in Basic Science

2000 James Ewing Basic Science Research Award; Society of Surgical Oncology

2000, 2002 Ward O. Griffen; Surgery Chief Residents Teaching Award, University of KY

2001, 2002 Abraham Flexner Master Educator Award for Outstanding

Teaching Contribution/Mentorship. A peer reviewed award recognizing outstanding faculty who had made significant contributions in the education program in the College of Medicine at the University of Kentucky.

2006 Senior Teaching Award, Department of Surgery, UMMC

2009 Mildred Mindell Cancer Foundation Humanitarian Award Recipient

2011 Faculty Scholar in Cancer Research Award, American Association for Cancer Research (AACR)

2008, 10, 12, 13, 15, 17-20 Baltimore Top Doctors, Surgical Oncology

2009-2020 America’s Top Doctors for Cancer, Castle Connolly Medical

2010-2020 America’s Top Doctors, Castle Connolly Medical

2011, 12, 13 Super Doctors; Awarded for top 5% of doctors in the Washington, DC-Baltimore-Northern Virginia.

2011-Present US News and World Report Top Doctors (Top 1%). Based on peer recognition and professional achievement.

2020 Baltimore Top Doctors, Colorectal Surgery

**VISITING PROFESSORSHIP**

1. Weill Cornell Medical College, New York. 10/28/2012.
2. NCI, Cairo, Egypt. 5/13/2014.
3. Aswan cancer Institute, Egypt. 9/26-9/30/2016
4. Washington Hospital Center, Washington, D.C. 1/17/2017
5. University of Sohag School of Medicine, Egypt. 8/1-8/4/2017
6. University of Helwan School of Medicine, Egypt. 11/26-11/27/2017.
7. Assiut University School of Medicine, Egypt. 11/11-11/14/2018.
8. University of Aswan School of Medicine, Egypt. 8/26/19-8/29/2019.

**CLINICAL ACTIVITIES**

**Surgical Expertise**

* Management of complex primary and advanced/metastatic gastrointestinal malignancies (esophageal, gastric, pancreatic, hepatobiliary, small bowel and colorectal).

- Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for abdominal carcinomatosis and peritoneal surface malignancies (Mesothelioma, Appendiceal, Colorectal, Gastric and Gynecological malignancies).

- Retroperitoneal and extremity soft tissue sarcoma.

- Minimally invasive surgery for cancer including laparoscopic and robotic surgery for colorectal, gastric, distal pancreatic, liver and adrenal tumors.

- Melanoma and other skin cancers.

**RESEARCH ACTIVITIES**

**Areas of Research Interest**

**Clinical Research**

The focus of my clinical research includes population studies of treatment outcomes in GI malignancies, development of a post-operative clinical care pathway following major gastrointestinal cancer surgery; identifying predictors of recurrence and survival in patients undergoing CRS and HIPEC, identification of factors that correlate with post-operative outcome and complications following CRS and HIPEC.

**Laboratory Research**:

Even though I currently have no independent laboratory, I continue to actively collaborate with several scientist both within the University of Maryland, other universities and the NIH. The focus of my laboratory research collaboration includes developing a personalized approach to targeted therapy for gastrointestinal malignancies and the role of the tumor microenvironment in tumor growth and metastasis.

**Current Projects**

Clinical Projects

1. Surgical Outcomes in patients with suspected/confirmed COVID-19 infection (PI)
2. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancies (PI)
3. Sarcoma treatment outcomes. (PI)
4. Outcomes after pancreatectomy. (PI)
5. Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients with Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study. (Co-PI)
6. Phase II Trial of Low Dose Whole Pelvic Radiotherapy with Concurrent Neoadjuvant FOLFOX for Patients with Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma. (Co-PI)
7. Retrospective analysis of all patients with gastrointestinal malignancies (primary and metastatic) treated with external beam radiation, brachytherapy, or radioembolization at University of Maryland Medical Center. (Co-PI)
8. Screening Protocol for Eligibility Determination for Clinical Trials Evaluating Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies. (Co-PI)
9. An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Gastrointestinal or Abdominal Malignancies or Melanoma to Be Used in Laboratory Research. (Co-PI)
10. Data and Biosample Repository and Maryland Cancer Survivorship Cohort. (Co-PI)
11. TERPS at UMMS (Training, Education for Robotic Performance with Simulation at University of Maryland Medical Systems). (Co-PI)
12. The EMPOWER Project: Employment and Potential Outcomes of Working through Cancer Treatment. (Co-PI)
13. Maryland Cancer Survivor Cohort. (Co-PI)
14. International Survey METSURVEY. (Co-PI)

**Research Collaboration**

Since my recruitment to the University of Maryland, I have continued to expand my collaborative research efforts in gastrointestinal malignancies. Over the past fourteen years, this growing research collaboration has led to several funded research grants. I currently participate in 2 NIH-funded grants with the NCI and George Town University.

**ADMINSTRATIVE SERVICE**

**Institutional Service (University of Kentucky)**

1999-2004 Medical Institutional Review Board, University of Kentucky

2001-2004 Anatomic Pathology Tissue Committee, University of Kentucky

2001-2004 Surgery Research Committee, University of Kentucky

2001-2004 Surgery Education Committee, University of Kentucky

2003-2004 Ethics Committee, University of Kentucky, College of Medicine

2003-2004 Admission Interviewer, University of Kentucky, College of Medicine

2003-2004 Infectious Biosafety Committee, University of Kentucky

2003-2004 Graduate Medical Education Internal Residency Reviewer for Surgery, University of Kentucky College of Medicine

**Institutional Service (University of Maryland)**

2004-Present Member, Program in Oncology, University of Maryland Greenebaum Cancer Center, UMSOM

2004-Present Surgical Residency interviewer, Department of Surgery, UMSOM

2004-2009 Chief, Section of Surgical Oncology, Division of General Surgery, Department of Surgery, UMSOM

2004-Present Surgeon Value Analysis Committee, Department of Surgery, UMSO

2004-2015, 17-19 Chair, Cancer Committee, University of Maryland Greenebaum Cancer Center, UMSOM

2004- 2009 Cancer Liaison Physician, University of Maryland Greenebaum Cancer Center, UMSOM

2005-Present Clinical Research Oversight Committee University of Maryland Greenebaum Cancer Center, UMSOM

2005-Pesent Consultant for surgical oncology issues to the Data & Safety Monitoring/Quality Assurance Committee (DSMQAC) of the UMGCC

2005-Present Course director, weekly multi-disciplinary gastro-intestinal tumor conference, University of Maryland Greenebaum Cancer Center, UMSOM (CME Credited)

2006-Present Clinical Research Committee Member of the UMGCC

2005-Present Tenure and Promotion Committee, Department of Surgery, UMSOM

2006-2015 Medical Director of the Surgical IMC unit, University of Maryland Medical center, Baltimore, MD

2006-2012 Chair, QA committee, Divisions of General Surgery/Surgical oncology/Emergency surgery, Department of Surgery, UMSOM

2006-Present Pathology and Biorepository Shared Service (PBSS) Advisory Committee,

2009-Present Front End Revenue Cycle Improvement Committee

2009-2011 Course director, Annual Multi-Disciplinary Gastro-Intestinal Cancer Symposium, UMSOM

2009-2012 Leader of the “Fairway to Life Breast Care Center” at UMGCC, accredited by the National Accreditation Program for Breast Care Center (NAPBC)

2009-2012 Head, Division of Surgical Oncology, Department of Surgery, UMSOM

2011-Present IRB consultant, UMSOM

2011 Search Committee, Chair, Department of Obstetrics and Gynecology, UMSOM

2012 Dissertation Faculty for graduate student Masayo Sato’s PhD thesis; “Impact of Erythropoiesis Stimulating Agents on Survival and Risk of Venous Thromboembolism Among Patients with Colorectal Cancer Receiving Chemotherapy”

2012-2015 Chair, Surgical Care Improvement Project (SCIP) core measure steering committee.

2012-2013 School of Medicine Council Alternate Representatives for the Department of Surgery

2012-Present VTE task force core measure committee member

2012- 2016 University of Maryland Medical Center’s EPIC Physician Advisory Group

2013-2016 University of Maryland, Baltimore Faculty Senate

2016- Present University of Maryland School of medicine Admission Committee.

2016- Present Surgical Oncology Quality Physician Champion

2016- Present UMMS Cancer Network Quality Physician Champion

2018- Present University of Maryland School of Medicine Council

**National Service**

2000-2001 Surgical Oncology Committee, Radiation Therapy Oncology Group

2000-2002 Member of the Council of Representatives of the Candidate and

Associate Society of the American College of Surgeons

2001-2002 Society of Surgical Oncology Fellowship-Research Grant Committee

2001 Chair, Surgery Study, RTOG-0012 2003-2007 Society of Surgical Oncology Training Committee 2004-2007 American Society of Breast Disease Membership Committee 2004 General Surgery News’ National Clinical Needs Assessment Panel

2009 Cytoreductive Surgery and HIPEC Training Initiative: First workshop for Department of Defense Surgical Oncologists

2011-2014 Society of Surgical Oncology Membership Committee

2011 Society of Interventional Radiology Foundation’s research consensus panel for the management of metastatic colorectal cancer.

2012 American College of Surgeons’ representative in the selection of the ACS/SSAT Health Policy Scholar

2012 The Jahnigen Career Development Awards (JCDA)/Grants for Early Medical/Surgical Subspecialists' Transition to Aging Research (GEMSSTAR) Selection Committee, American College of Surgeons (ACS)

2013 Discussant in the Surgical Forum program, ACS Annual Clinical Congress, October, 2013

2013-2019 American College of Surgeons, International Relations Committee

2014-2017 AJCC Expert Panel Member of the Lower GI (*anus, appendix carcinoma, colon and rectum*): AJCC Cancer Staging System, 8th Edition

2016-2017 Vice Chair, International Fellowship Subcommittee, American College of Surgeons

2017-2019 Chair, International Fellowship Subcommittee, American College of Surgeons

2017- Present The Alliance/ACS CRP Cancer Care Standards Development Committee, American College of Surgeons

2017- Present The Alliance/ACS CRP Dissemination and Implementation Committee, American College of Surgeons

2019-2021 Committee member, Colorectal Cancer Disease site working group, Society of Surgical Oncology

2019, 2020 Abstract Reviewers, SSO Annual Scientific Cancer Symposium

2019 Moderator, Mid-Atlantic Ovarian Cancer Symposium. Bethesda, MD. June 15, 2019

2020 Expert panel member, SSO Virtual Tumor Board: Colorectal disease and COVID-19

2019-2021 Vice Chair, International Relationship Committee, ACS

2020-2021 Treasurer, Maryland Chapter, ACS

2020 Expert panel member, SSO Virtual Tumor Board: Colorectal disease. 9/28/2020

2020- Present AJCC Expert Panel Member of the Lower GI (*anus, appendix carcinoma, colon and rectum*): AJCC Cancer Staging System, 9th Edition

2021-2023 Committee member, Colorectal Cancer Disease site working group, Society of Surgical Oncology

2021-2026 Consultant for the Complex General Surgical Oncology Continuous Certification Assessment, American Board of Surgery.

**International Service**

2005, 2006 International College of Surgeons, AMA Advisory Task Force Committee

2009 Chair, Pancreatic Cancer Session.2nd World Cancer Congress, Beijing,

China. 5/2009

2010 Moderator, Fifth International Symposium on Regional Cancer Therapies,

Carolina, Puerto Rico. 2/2010

2011 Chair, Esophageal & Gastrointestinal Session, 4th World Cancer Congress, Dalian, China. 6/2011

2011 Regent for the State of Maryland, International College of Surgeons

2012 Chair, Surgical Oncology Session, 1st Conference of the Egyptian Chapter of the American College of Surgeons. 9/2012

2013, 2014 Scholarship & Research Committee, International College of Surgeons

2013 Chair, Surgical Oncology Session, 2nd Conference of the Egyptian Chapter of the American College of Surgeons. 5/2013

2013- Present Advisory Board, Ain Shams Medical Students Research Association (AMSRA)

2014 Panelist & invited speaker at 3rd International Gastrointestinal and Liver Oncology Conference for “Tailoring Guidelines in multidisciplinary management of metastatic colorectal cancer aiming at regional recommendation” session. Cairo, Egypt.

2014-2016 Expert Panel Member, Lower GI, American Joint Commission on Cancer (AJCC), 8th Edition.

2015 Panelist & invited speaker at the Peritoneal Surface Malignancy Experts Meeting. May 8, 9 2015, Athens, Greece.

2016 Co-Chair, HIPEC symposium at International Congress of Hyperthermic Oncology meeting. New Orleans, USA 4/2016

2016 Discussant, case presentations: Peritoneal Metastasis from Gastric cancer. 10th International Congress on Peritoneal Surface Malignancies. Washington, DC. 11-18-2016

2016 Meet the Professor Session: Pseudomyxoma Peritonei: Follow-up and Management of Recurrent disease. 10th International Congress on Peritoneal Surface Malignancies. Washington, DC. 11-19-2016

2018 Scientific Committee, 18th Annual Conference of Egyptian Society of Surgical Oncology, Egyptian Cancer Society, Society of Surgical Oncology (USA). Cairo, Egypt 4/11-4/13/2018.

2018 Meet the Professor Session: Management of IPMN of Pancreas. 18th Annual Conference of Egyptian Society of Surgical Oncology, Egyptian Cancer Society, Society of Surgical Oncology (USA). Cairo, Egypt 4/11-4/13/2018.

2018 Faculty; The 2nd International Workshop: A comprehensive Approach for The Management of Peritoneal Malignancy with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Cairo, Egypt. 4/11-4/12/2018.

2018 Meet The Expert Session: Pseudomyxoma Peritonii; Imaging, Approach -Follow up & Management of Recurrent Disease. The 2nd International Workshop: A comprehensive Approach for The Management of Peritoneal Malignancy with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Cairo, Egypt. 4/12/2018.

2018 Video Session: **RUQ** (Right Abdominal wall -Right Diaphragmatic crus resection -Gastric wall Resection -Bursa omentalis). The 2nd International Workshop: A comprehensive Approach for The Management of Peritoneal Malignancy with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Cairo, Egypt. 4/12/2018.

2019 Video Session: Left upper abdominal quadrantectomy. Surgi-Alex 2019, University of Alexandria, Alexandria, Egypt 4/7/19-4/12/19.

**EDITORIAL BOARD**

*2015- Present Annals of Surgical Oncology Section of Gastrointestinal Oncology*

*2019- Present PLOS ONE*

**AD HOC JOURNAL REVIEWER**

*Annals of Surgery*

*Annals of Surgical Oncology*

*Journal of Clinical Oncology*

*Journal of The American College of Surgeon*

*Cancer*

*Surgery: Current Research*

*Journal of Surgical Research*

*Surgical Innovation*

*International journal Of Hyperthermia*

*Encyclopedia of Medical Genomics & Proteomics (EMGP)*

*Journal of Surgical Oncology*

*Clinical Colorectal Cancer*

*Current Medical Literature in Colorectal Cancer*

**NIH GRANT REVIEWERS**

**Meeting Title:** Subcommittee J - Career Development

**Meeting Identifier:** 2013/05 NCI-J

**Meeting Dates:** 03/05/2013-03/06/2013

07/01/2013-07/02/2013

**TEACHING SERVICE**

**Medical Students**

2004-Present Attending Physician, in-patient surgical service

2-3 students

1-2 contact hours/day, 9 months/year

2004-Present Outpatient multi-disciplinary surgical oncology clinic (1day/week)

1-2 students

6 contact hours/clinic day, 9 months/year

2004-Present Weekly inpatient surgical oncology team teaching rounds (1day/week)

2004-Present 3rd year medical students lecture series for each rotation:

* Colorectal cancer
* Hepatic malignancies
* Sarcoma

2005-2009 Mentor and course director for sub-I students rotating through Surgical Oncology (GSUR 549). 1 student/3 weeks through weeks 1-44

2004-2015 Initiated and in charge of weekly didactic surgical oncology teaching conference, during which each student is required to give a power point presentation on a cancer-related topic

2005-Present Weekly multi-disciplinary gastro-intestinal tumor conference (CME-accredited)

2009-Present Instructor**,** Clinical Applications of Anatomy in Surgery (GSUR 540)

2011-2012 Mentor and course director for sub-I students rotating through Surgical Oncology (GSUR 549). 1 student/3 weeks through weeks 1-44

2014 Medical student research day Judge

2016 Medical student research day Judge

2020 Medical student research day Judge

**Residents/Fellows**

2004-Present General surgery resident lecture series:

* Sarcoma
* Colon and Rectal Cancer
* Gastric Cancer
* Hepatobiliary-pancreatic malignancies

2004-Present Initiated and in charge of weekly didactic surgical oncology teaching conference, during which each resident is required to give a power point presentation on a cancer-related topic

2004-Present Outpatient multi-disciplinary surgical oncology clinic (1day/week)

2004-Present Weekly inpatient surgical oncology team teaching rounds (1day/week)

2005-Present Weekly multidisciplinary gastro-intestinal tumor conference

2006-Present Radiation oncology residents/fellows lecture series

2006-Present Medical Oncology fellows lecture series

2007-Present MOC oral examination faculty

**Course Instructor (Graduate Students)**

2007-2011 Clinical Cancer Genetics Course-HGEN 760 (2 contact hours, 6-8 graduate students/year):

* Overview of Colorectal Cancer

2008-2010 Cancer Biology Course-GPILS 665 (6 contact hours, 6-8 graduate students/year):

* Clinical Aspects of Breast Cancer
* Diagnosis and Management of Colorectal Cancer
* Hereditary Cancer Syndromes
* Prophylactic Cancer Surgery

**Course Director (CME Credited)**

2005-Present Course director, weekly multidisciplinary gastro-intestinal tumor conference, University of Maryland Greenebaum Cancer Center, UMSOM

2009-2011 1st, 2nd, and 3rd Annual Multidisciplinary Gastro-Intestinal Cancer Symposium, UMSOM

2013 4th Annual Multidisciplinary Gastro-Intestinal Cancer Symposium, UMSOM

2014 The 3rd Annual Update and Workshop on Management of Peritoneal Surface Malignancies, UMSOM

2015 The 9th Annual Cancer Symposium, “Cancer prevention, screening and early diagnosis” UM-SJMC Cancer institute, 11/2015

2016 The 10th Annual Cancer Symposium, “Cancer in Women”. UM-SJMC Cancer institute, 11/2016

2017 The 11th Annual Cancer Symposium “Integrative Cancer Care and Symptom Management”, UM-SJMC Cancer institute, 11/2017

2018 The 12th Annual Cancer Symposium “Management of Patients During Active Cancer Treatment”, UM-SJMC Cancer institute, 11/2018

## PRECEPTOR/MENTORSHIP ACTIVITIES

**Students**

1999-2004 Research in Surgery: Course #SUR866 for 4th year medical students, University of Kentucky.

1999-2004 Preceptor for Summer Research Apprentices (8 weeks) for undergraduate students, University of Kentucky.

1999-2004 Research mentor for undergraduate students Biology course # 395, University of Kentucky.

2000-2004 Mentor for Summer Research Fellowship Program (8 weeks) for medical students, University of Kentucky.

2005-2009 Mentor and course director for sub-I students rotating through Surgical Oncology (GSUR 549), UMSOM.1 student/3 weeks through weeks 1-44.

**Post-Doctoral**

1998-2004 Walid Al-Jumaily, PhD, University of Kentucky

2000-2003 Mentor for the Future Professor Program at University of Louisville for Graduate student (Emad Boctor, PhD), currently Assistant Professor of Surgery at Johns Hopkins.

2003-2004 Shaun McKenzie, MD; currently Assistant Professor of Surgery at University of Kentucky.

2010-2011 Faculty advisor for PhD candidate; Masayo Sato, BSPharm, MS, Department of Pharmaceutical Health Services Research, University of Maryland

2012 Dissertation Faculty for graduate student Masayo Sato’s PhD thesis; “Impact of Erythropoiesis Stimulating Agents on Survival and Risk of Venous Thromboembolism Among Patients with Colorectal Cancer Receiving Chemotherapy”

9/2013-3/2014 Preceptor for Med onc fellow from Turkey, Dr. Ece Esin

9/2014-11/2014 Preceptor for Surgeon from Sarajevo, Dr. Sadat Pausina

2018-2021 Faculty advisor for Ph.D. candidate; Bahaa Eldin Eldokany, MD, Department of Surgical Oncology, NCI, Egypt.

2018-2020 Faculty advisor for Ph.D. candidate; Sherif Khiralla, MD, Department of Surgical Oncology, NCI, Egypt

**GRANT SUPPORT**

**Active Grants**

00/01/19-08/31/22 N. Hanna (Co. Inv. 5%; PI-Chung (Georgetown University)

“Gamma-OHPdG as a Prognostic Biomarker of HCC Recurrence and its Prevention”

**NIH/NCI U01 CA220477-01A1**

**Completed Grants**

1999 N. Hanna (PI)

“Exploitation of Tumor Hypoxia for Pancreatic Cancer Radiosensitization”

American Cancer Society

**R01 HD3211**

$ 20,000.00 (All Direct Costs)

2000 N. Hanna (PI)

“An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis actor alpha (TNFerade Biologic) Gene Therapy with

Radiation for Locally Advanced, Recurrent or Metastatic Solid

Tumors”

Gen Vec, Inc.

$121,592.000 (Direct cost: $ 96,502.00)

2000 N. Hanna (PI)

“Exploitation of Tumor Hypoxia for Pancreatic Cancer Radiosensitization”

Society of Surgical Oncology Fellowship award for Basic Research

$30,000.00 (All Direct Costs)

2001 N. Hanna (Study Surgery Chair)

RTOG #R-0012

American College of Radiology

6,300.00 (Direct costs: $5,000.00)

2001 – 2004 N. Hanna (PI)

“An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic

with Radiation Therapy as an Adjunct to Surgery or for Palliation in Soft

Tissue Sarcoma of the Extremities”

Gen Vec, Inc

$29,321.00 (Direct cost: $ 23,271.00)

2002 N. Hanna (PI)

Surgical Oncology Research Fund

Private Donation

$ 100,000.00

2002 – 2004 N. Hanna (PI)

“A Randomized Phase II Study of TNFerade Biologic with 5-FU and

Radiation Therapy for First-Line Treatment of Unresectable Locally

Advanced Pancreatic Cancer”

Gen Vec, Inc

$119,973.67 (Direct cost: $ 95,217.00)

2002-2004 N. Hanna

Salary support for clinical research nurse coordinator

GenVec, Inc

$75,600.00, annually (Direct costs: $ 60,000.00)

2003 – 2004 N. Hanna (PI)

“Phase II, Multi-center single arm evaluation of perioperative chemo

radiation plus TNFerade Biologic prior to esophagectomy for locally

advanced resectable esophageal cancer”

Gen Vec, Inc

$ 171,263 (Direct cost: $ 135,923.00)

08/01/04 N Hanna (Co-Inv, PI-Alfred Cohen)

Pancreatic Initiative Director, FTE .10

“Cancer Prevention and Control Earmarks. An integrated, population

based community and cancer center program, with focus on early

detection, molecular epidemiology and state-of-the art treatment for lung,

esophageal, liver and pancreatic cancers”

Center for Disease Control

$955,705.00 annually for 5 years (Direct cost: $758,496.00)

4/01/2007-9/02/2008 N. Hanna (Co-Inv, 7%; PI-Daniel Mullins)

“Use and Outcomes of Novel Chemotherapeutic Agents in Colorectal

Cancer”

Sanofi-Aventis

$650,514.00

9/01/2007-6/31/2008 N. Hanna (PI)

Educational Grant

Schering –Plough

$5000.00

1/01/2008-6/30/2009 N. Hanna (Co. Inv, 5%; PI-Daniel Mullins)

“Treatment Patterns, Costs, and Outcomes across Various Cancer Sites”

Sanofi-Aventis

$690,000.00

3/01/2009-3/01/2010 N. Hanna (Co. Inv. 5%; PI-Daniel Mullins)

“Treatment Patterns, Outcomes and Costs related to Colon Cancer”

Sanofi-Aventis

$319,337.00

1/02/2010-8/23/2010 N. Hanna (Co. Inv. 5%; PI-Daniel Mullins)

“Patient Flow and VTE incidence among Colorectal Cancer Patients”

Sanofi-Aventis

$155,115.00

5/2010 Nader Hanna (PI)

Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary

Efficacy Study of Intratumoral Administration of DTA-H19 in Patients

with Unresectable Pancreatic Cancer

BioCancell

11/1/10-6/30/12 N. Hanna (Co. Inv. 7.5%; PI-Fadia Shaya)

Treatment Selection and CER of Liver Cancer Treatment

Bayer

$405,999.00

2012 N. Hanna

“A Phase III Study of Chemotherapy and Chemoradiotherapy with or without Hyper-Acute-Pancreas (algenpantucel-L) in Subjects with Surgically Resected Pancreatic Cancer”

Novartis

$173,614.35

**PUBLICATIONS**

**Peer Reviewed Journal Articles**

## Complete List of Published Work in My Bibliography:

## https://www.ncbi.nlm.nih.gov/myncbi/nader.hanna.1/bibliography/public/

1. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, **Hanna NN**, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. [Spatial and temporal control of gene therapy using ionizing radiation.](http://www.ncbi.nlm.nih.gov/pubmed/7585181) Nat Med. 1995 Aug;1(8):786-91. PubMed PMID: 7585181.
2. **Hanna NN**, O'Donnell K, Wolfe GR. [Alveolar soft part sarcoma metastatic to the breast.](http://www.ncbi.nlm.nih.gov/pubmed/8606550) J Surg Oncol. 1996 Feb;61(2):159-62. PubMed PMID: 8606550.
3. **Hanna NN**, Hallahan DE, Wayne JD, Weischselbaum RR. [Modification of the Radiation Response by the Administration of Exogenous Genes.](http://www.ncbi.nlm.nih.gov/pubmed/10717189) Semin Radiat Oncol. 1996 Oct;6(4):321-328. PubMed PMID: 10717189.
4. Mauceri HJ, **Hanna NN**, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996 Oct 1;56(19):4311-4. PubMed PMID: 8813113.
5. **Hanna NN**, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR. [Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts.](http://www.ncbi.nlm.nih.gov/pubmed/9331076) Cancer Res. 1997 Oct 1;57(19):4205-9. PubMed PMID: 9331076.
6. Mauceri HJ, **Hanna NN**, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. [Combined effects of angiostatin and ionizing radiation in antitumour therapy.](http://www.ncbi.nlm.nih.gov/pubmed/9685160) Nature. 1998 Jul 16;394(6690):287-91. PubMed PMID: 9685160.
7. **Hanna NN**, McGrath PC, Sloan DA, Kenady DE. [Advances in the pathogenesis and treatment of thyroid cancer.](http://www.ncbi.nlm.nih.gov/pubmed/9914877) Curr Opin Oncol. 1999 Jan;11(1):42-7. Review. PubMed PMID: 9914877.
8. Mauceri HJ, **Hanna NN**, Staba MJ, Beckett MA, Kufe DW, Weichselbaum RR. [Radiation-inducible gene therapy.](http://www.ncbi.nlm.nih.gov/pubmed/10196676) C R Acad Sci III. 1999 Feb-Mar;322(2-3):225-8. Review. PubMed PMID: 10196676.
9. **Hanna NN**, Kenady DE. [Hypertension in patients with pheochromocytoma.](http://www.ncbi.nlm.nih.gov/pubmed/10981118) Curr Hypertens Rep. 1999 Dec;1(6):540-5. PubMed PMID: 10981118.
10. **Hanna NN**, Kenady DE. [Advances in the management of adrenal tumors.](http://www.ncbi.nlm.nih.gov/pubmed/10687729) Curr Opin Oncol. 2000 Jan;12(1):49-53. Review. PubMed PMID: 10687729.
11. **Hanna NN**, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR. [Antitumor interaction of short-course endostatin and ionizing radiation.](http://www.ncbi.nlm.nih.gov/pubmed/11079167) Cancer J. 2000 Sep-Oct;6(5):287-93. PubMed PMID: 11079167.
12. Mohiuddin M, Hayne M, Regine WF, **Hanna N**, Hagihara PF, McGrath P, Marks GM. [Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers.](http://www.ncbi.nlm.nih.gov/pubmed/11072165) Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1075-80. PubMed PMID: 11072165.
13. Sharma A, Mani S, **Hanna N**, Guha C, Vikram B, Weichselbaum RR, Sparano J, Sood B, Lee D, Regine W, Muhodin M, Valentino J, Herman J, Desimone P, Arnold S, Carrico J, Rockich AK, Warner-Carpenter J, Barton-Baxter M. [Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/11399232) *Hum Gene Ther.* 2001 Jun 10;12(9):1109-31. PubMed PMID: 11399232.
14. Mohiuddin M, Kudrimoti M, Regine WF, McGrath PC, **Hanna N**, John W. [Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.](http://www.ncbi.nlm.nih.gov/pubmed/12074325) Cancer J. 2002 May-Jun;8(3):255-62. PubMed PMID: 12074325.
15. **Hanna NN**, Guillem J, Dosoretz A, Steckelman E, Minsky BD, Cohen AM. [Intraoperative parasympathetic nerve stimulation with tumescence monitoring during total mesorectal excision for rectal cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12375756) J Am Coll Surg. 2002 Oct;195(4):506-12. PubMed PMID: 12375756.
16. Salloum RM, Saunders MP, Mauceri HJ, **Hanna NN**, Gorski DH, Posner MC, Stratford IJ, Weichselbaum RR. [Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay.](http://www.ncbi.nlm.nih.gov/pubmed/12575775) *Am Surg*. 2003 Jan;69(1):24-7. Erratum in: *Am Surg*. 2003 Apr;69(4):362. PubMed PMID: 12575775.
17. **Hanna NN**, Mentzer RM Jr. [Molecular genetics and management strategies in hereditary cancer syndromes.](http://www.ncbi.nlm.nih.gov/pubmed/12674901) J Ky Med Assoc. 2003 Mar;101(3):100-7. Review. PubMed PMID: 12674901.
18. **Hanna NN**, Cohen AM. [Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy.](http://www.ncbi.nlm.nih.gov/pubmed/15025793) *Clin Colorectal Cancer*. 2004 Feb;3(4):215-22. Review. PubMed PMID: 15025793.
19. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, **Hanna N**. [TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/14726502) *J Clin Oncol*. 2004 Feb 15;22(4):592-601. Epub 2004 Jan 15. PubMed PMID: 14726502.
20. **Hanna NN**. [Radiofrequency ablation of primary and metastatic hepatic malignancies.](http://www.ncbi.nlm.nih.gov/pubmed/15285816) Clin Colorectal Cancer. 2004 Jul;4(2):92-100. Review. PubMed PMID: 15285816.
21. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, **Hanna N**, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. [A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.](http://www.ncbi.nlm.nih.gov/pubmed/15355902) Clin Cancer Res. 2004 Sep 1;10(17):5747-53. PubMed PMID: 15355902.
22. Gaugler JE, **Hanna N**, Linder J, Given CW, Tolbert V, Kataria R, Regine WF. [Cancer caregiving and subjective stress: a multi-site, multi-dimensional analysis.](http://www.ncbi.nlm.nih.gov/pubmed/15750995) Psychooncology. 2005 Sep;14(9):771-85. PubMed PMID: 15750995.
23. Saidi RF, ReMine SG, Dudrick PS, **Hanna NN**. [Is there a role for palliative gastrectomy in patients with stage IV gastric cancer?](http://www.ncbi.nlm.nih.gov/pubmed/16369718) World J Surg. 2006 Jan;30(1):21-7. PubMed PMID: 16369718.
24. Mohiuddin M, Winter K, Mitchell E, **Hanna N**, Yuen A, Nichols C, Shane R, Hayostek C, Willett C; Radiation Therapy Oncology Group Trial 0012. [Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.](http://www.ncbi.nlm.nih.gov/pubmed/16446336) J Clin Oncol. 2006 Feb 1;24(4):650-5. PubMed PMID: 16446336.
25. Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, Baratti D, Bartlett D, Barone R, Barrios P, Bieligk S, Bretcha-Boix P, Chang CK, Chu F, Chu Q, Daniel S, de Bree E, Deraco M, Dominguez-Parra L, Elias D, Flynn R, Foster J, Garofalo A, Gilly FN, Glehen O, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Goodman M, Gushchin V, **Hanna N**, Hartmann J, Harrison L, Hoefer R, Kane J, Kecmanovic D, Kelley S, Kuhn J, Lamont J, Lange J, Li B, Loggie B, Mahteme H, Mann G, Martin R, Misih RA, Moran B, Morris D, Onate-Ocana L, Petrelli N, Philippe G, Pingpank J, Pitroff A, Piso P, Quinones M, Riley L, Rutstein L, Saha S, Alrawi S, Sardi A, Schneebaum S, Shen P, Shibata D, Spellman J, Stojadinovic A, Stewart J, Torres-Melero J, Tuttle T, Verwaal V, Villar J, Wilkinson N, Younan R, Zeh H, Zoetmulder F, Sebbag G; Society of Surgical Oncology Annual Meeting. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.](http://www.ncbi.nlm.nih.gov/pubmed/17072675) Ann Surg Oncol. 2007 Jan;14(1):128-33. Epub 2006 Oct 28. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S334-5. PubMed PMID: 17072675.
26. Alexander HR, **Hanna N**, Pingpank JF. [Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma.](http://www.ncbi.nlm.nih.gov/pubmed/17633065) Cancer Treat Res. 2007;134:343-55. Review. PubMed PMID: 17633065.
27. Regine WF, **Hanna N**, Garofalo MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M. Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):172-7. Epub 2007 Feb 2. PubMed PMID: 17276612.
28. Nugent SL, Cunningham SC, Alexiev BA, Bellavance E, Papadimitriou JC, **Hanna N**. [Composite signet-ring cell/neuroendocrine carcinoma of the stomach with a metastatic neuroendocrine carcinoma component: a better prognosis entity.](http://www.ncbi.nlm.nih.gov/pubmed/17988399) Diagn Pathol. 2007 Nov 7;2:43. PubMed PMID: 17988399; PubMed Central PMCID: PMC2174438.
29. Young PE, Oosterveen S, **Hanna N**, Darwin PE. [Presacral schwannoma diagnosed by EUS-guided FNA.](http://www.ncbi.nlm.nih.gov/pubmed/17981275) Gastrointest Endosc. 2008 Feb;67(2):383-5. Epub 2007 Nov 5. PubMed PMID: 17981275.
30. Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, **Hanna N**, Pandya N, Mullins CD. [Trends in disparities in receipt of adjuvant therapy for elderly stage III colon cancer patients: the role of the medical oncologist evaluation.](http://www.ncbi.nlm.nih.gov/pubmed/19786906) Med Care. 2009 Dec;47(12):1229-36. doi: 10.1097/MLR.0b013e3181b58a85. PubMed PMID: 19786906.
31. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):158-62. doi: 10.1016/j.ijrobp.2009.10.043. Epub 2010 Apr 14. PubMed PMID: 20399035.
32. Turner PL, Ilano AG, Zhu Y, Johnson SB, **Hanna N**. [ACS-NSQIP criteria are associated with APACHE severity and outcomes in critically ill surgical patients.](http://www.ncbi.nlm.nih.gov/pubmed/21356486) J Am Coll Surg. 2011 Mar;212(3):287-94. doi: 10.1016/j.jamcollsurg.2010.12.011. PubMed PMID: 21356486.
33. **Hanna NN**, Bellavance E, Keay T. [Palliative surgical oncology.](http://www.ncbi.nlm.nih.gov/pubmed/21419257) Surg Clin North Am. 2011 Apr;91(2):343-53, viii. doi: 10.1016/j.suc.2010.12.004. PubMed PMID: 21419257.
34. Costello LC, Levy BA, Desouki MM, Zou J, Bagasra O, Johnson LA, **Hanna N**, Franklin RB. [Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/21613827) Cancer Biol Ther. 2011 Aug 15;12(4):297-303. Epub 2011 Aug 15. PubMed PMID: 21613827; PubMed Central PMCID: PMC3173731.
35. Hsiao FY, Mullins CD, Onukwugha E, Pandya N, **Hanna N**. [Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.](http://www.ncbi.nlm.nih.gov/pubmed/21831168) J Am Geriatr Soc. 2011 Sep;59(9):1717-23. doi: 10.1111/j.1532-5415.2011.03501.x. Epub 2011 Aug 10. PubMed PMID: 21831168.
36. **Hanna NN**, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data. Colorectal Dis. 2012 Jan;14(1):48-55. doi: 10.1111/j.1463-1318.2011.02545.x. PubMed PMID: 21689262.
37. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, **Hanna N**, Chang KJ, Javle M, Posner M, Waxman I, Reid A, Erickson R, Canto M, Chak A, Blatner G, Kovacevic M, Thornton M. [EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.](http://www.ncbi.nlm.nih.gov/pubmed/22248601) Gastrointest Endosc. 2012 Feb;75(2):332-8. doi: 10.1016/j.gie.2011.10.007. PubMed PMID: 22248601; PubMed Central PMCID: PMC4380192.
38. Janne d'Othée B, Sofocleous CT, **Hanna N**, Lewandowski RJ, Soulen MC, Vauthey JN, Cohen SJ, Venook AP, Johnson MS, Kennedy AS, Murthy R, Geschwind JF, Kee ST. [Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.](http://www.ncbi.nlm.nih.gov/pubmed/22264550) J Vasc Interv Radiol. 2012 Feb;23(2):153-63. doi: 10.1016/j.jvir.2011.12.003. PubMed PMID: 22264550; PubMed Central PMCID: PMC4352314.
39. Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, **Hanna N**, Alexander HR, Hussain SP. [DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/22363658) PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20. PubMed PMID: 22363658; PubMed Central PMCID: PMC3282755.
40. **Hanna N**, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A. [Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.](http://www.ncbi.nlm.nih.gov/pubmed/22498722) Cancer Gene Ther. 2012 Jun;19(6):374-81. doi: 10.1038/cgt.2012.10. Epub 2012 Apr 13. PubMed PMID: 22498722.
41. Franklin RB, Levy BA, Zou J, **Hanna N**, Desouki MM, Bagasra O, Johnson LA, Costello LC. [ZIP14 zinc transporter downregulation and zinc depletion in the development and progression of hepatocellular cancer.](http://www.ncbi.nlm.nih.gov/pubmed/21373779) J Gastrointest Cancer. 2012 Jun;43(2):249-57. doi: 10.1007/s12029-011-9269-x. PubMed PMID: 21373779; PubMed Central PMCID: PMC3724761.
42. Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, **Hanna N**, Chak A, Soetikno R. [Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.](http://www.ncbi.nlm.nih.gov/pubmed/22520270) Gastrointest Endosc. 2012 Jun;75(6):1139-46.e2. doi: 10.1016/j.gie.2012.01.042. Epub 2012 Apr 18. PubMed PMID: 22520270; PubMed Central PMCID: PMC4543382.
43. Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, **Hanna N**. [Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/22020739) Cancer. 2012 Jun 15;118(12):3173-81. doi: 10.1002/cncr.26613. Epub 2011 Oct 21. PubMed PMID: 22020739.
44. Yovino S, Maidment BW 3rd, Herman JM, Pandya N, Goloubeva O, Wolfgang C, Schulick R, Laheru D, **Hanna N**, Alexander R, Regine WF. [Analysis of local control in patients receiving IMRT for resected pancreatic cancers.](http://www.ncbi.nlm.nih.gov/pubmed/22284684) Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):916-20. doi: 10.1016/j.ijrobp.2011.08.026. Epub 2012 Jan 25. PubMed PMID: 22284684; PubMed Central PMCID: PMC3556989.
45. **Hanna N**, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD. [Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer.](http://www.ncbi.nlm.nih.gov/pubmed/22767876) Oncologist. 2012;17(9):1191-7. Epub 2012 Jul 5. PubMed PMID: 22767876; PubMed Central PMCID: PMC3448412.
46. Mahmood U, Errens M, Zimrin A, **Hanna N**, Amin P, Sharma N. [The remarkably distensible stomach: Case report highlighting the implications of gastric filling on radiation treatment planning for gastric lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/24674162) Pract Radiat Oncol. 2012 Oct-Dec;2(4):265-9. doi: 10.1016/j.prro.2011.08.006. Epub 2011 Oct 1. PubMed PMID: 24674162.
47. Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, **Hanna N**, Alexander HR, Maitra A, Hussain SP. [Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/22821831) Int J Cancer. 2013 Feb;132(4):785-94. doi: 10.1002/ijc.27736. PubMed PMID: 22821831; PubMed Central PMCID: PMC3488363.
48. Zhu Y, **Hanna N**, Boutros C, Alexander HR Jr. [Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.](http://www.ncbi.nlm.nih.gov/pubmed/23450068) J Gastrointest Oncol. 2013 Mar;4(1):62-71. doi: 10.3978/j.issn.2078-6891.2012.053. PubMed PMID: 23450068; PubMed Central PMCID: PMC3562622.
49. Turner KM, **Hanna NN**, Zhu Y, Jain A, Kesmodel SB, Switzer RA, Taylor LM, Richard Alexander H Jr. [Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23456383) Ann Surg Oncol. 2013 Apr;20(4):1068-73. doi: 10.1245/s10434-012-2789-1. Epub 2013 Mar 2. PubMed PMID: 23456383.
50. Lissauer ME, Diaz JJ, Narayan M, Shah PK, **Hanna NN**. [Surgical intensive care unit admission variables predict subsequent readmission.](http://www.ncbi.nlm.nih.gov/pubmed/23711267) Am Surg. 2013 Jun;79(6):583-8. PubMed PMID: 23711267.
51. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, **Hanna N**, Turner K, Beresneva T, Zhu Y. [Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.](http://www.ncbi.nlm.nih.gov/pubmed/23489943) Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13. PubMed PMID: 23489943; PubMed Central PMCID: PMC3734959.
52. Mohiuddin M, Paulus R, Mitchell E, **Hanna N**, Yuen A, Nichols R, Yalavarthi S, Hayostek C, Willett C. [Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23545284) Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):523-8. doi: 10.1016/j.ijrobp.2013.02.020. Epub 2013 Mar 29. PubMed PMID: 23545284; PubMed Central PMCID: PMC4201041.
53. Breunig IM, Shaya FT, Hanna N, Seal B, Chirikov VV, Daniel Mullins C. Transarterial chemoembolization treatment: association between multiple treatments, cumulative expenditures, and survival. Value Health. 2013 Jul-Aug;16(5):760-8. doi: 10.1016/j.jval.2013.03.1630. Epub 2013 May 28. PubMed PMID: 23947969.
54. Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, **Hanna N**, Alexander HR, Hussain SP. [FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23801748) Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25. PubMed PMID: 23801748; PubMed Central PMCID: PMC3766408.
55. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, **Hanna N**, Alexander HR, Hussain SP. [Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23918603) Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5. PubMed PMID: 23918603; PubMed Central PMCID: PMC3778077.
56. Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, **Hanna NN**, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE. [Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23871153) Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009. Epub 2013 Jul 18. PubMed PMID: 23871153.
57. Reese ES, Onukwugha E, **Hanna N**, Seal BS, Mullins CD. [Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/24403264) Cancer Med. 2013 Dec;2(6):907-15. doi: 10.1002/cam4.143. Epub 2013 Oct 10. PubMed PMID: 24403264; PubMed Central PMCID: PMC3892395.
58. Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, **Hanna N**. [Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.](http://www.ncbi.nlm.nih.gov/pubmed/24293197) Pharmacoeconomics. 2014 Jan;32(1):63-74. doi: 10.1007/s40273-013-0109-7. PubMed PMID: 24293197.
59. Zheng Z, **Hanna N**, Onukwugha E, Reese ES, Seal B, Mullins CD. [Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/24403130) Cancer Med. 2014 Feb;3(1):124-33. doi: 10.1002/cam4.176. Epub 2014 Jan 7. PubMed PMID: 24403130; PubMed Central PMCID: PMC3930397.
60. Zheng Z, **Hanna N**, Onukwugha E, Bikov KA, Mullins CD. [Hospital center effect for laparoscopic colectomy among elderly stage I-III colon cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/23817508) Ann Surg. 2014 May;259(5):924-9. doi: 10.1097/SLA.0b013e31829d0468. PubMed PMID: 23817508.
61. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, **Hanna N**, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. [Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.](http://www.ncbi.nlm.nih.gov/pubmed/23793364) Ann Surg Oncol. 2014 May;21(5):1501-5. doi: 10.1245/s10434-013-3061-z. Epub 2013 Jun 21. PubMed PMID: 23793364.
62. Zheng Z, Onukwugha E, **Hanna N**, Bikov K, Seal B, Mullins CD. [Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/25022528) Adv Ther. 2014 Jul;31(7):724-34. doi: 10.1007/s12325-014-0134-8. Epub 2014 Jul 15. PubMed PMID: 25022528; PubMed Central PMCID: PMC4115177.
63. Thom KA, Standiford HC, Johnson JK, **Hanna N**, Furuno JP. [Effectiveness of an antimicrobial polymer to decrease contamination of environmental surfaces in the clinical setting.](http://www.ncbi.nlm.nih.gov/pubmed/25026625) Infect Control Hosp Epidemiol. 2014 Aug;35(8):1060-2. doi: 10.1086/677159. Epub 2014 Jun 20. PubMed PMID: 25026625; PubMed Central PMCID: PMC4294176.
64. Steinhardt JJ, Peroutka RJ, Mazan-Mamczarz K, Chen Q, Houng S, Robles C, Barth RN, DuBose J, Bruns B, Tesoriero R, Stein D, Fang R, **Hanna N**, Pasley J, Rodriguez C, Kligman MD, Bradley M, Rabin J, Shackelford S, Dai B, Landon AL, Scalea T, Livak F, Gartenhaus RB. [Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.](http://www.ncbi.nlm.nih.gov/pubmed/25320244) Blood. 2014 Dec 11;124(25):3758-67. doi: 10.1182/blood-2014-07-589689. Epub 2014 Oct 15. PubMed PMID: 25320244; PubMed Central PMCID: PMC4263984.
65. Bikov KA, Mullins CD, Seal B, Onukwugha E, Hanna N. Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. Med Care. 2015 Aug; 53(8):e58-64. PubMed. PMID: 23552436
66. Chirikov VV, Mullins CD, **Hanna N**, Breunig IM, Seal B, Shaya FT. [Multispecialist Care and Mortality in Hepatocellular Carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/24064759) Am J Clin Oncol. 2015 Dec;38(6):557-63. doi: 10.1097/COC.0000000000000000. PubMed PMID: 24064759.
67. Asare EA, Compton CC, **Hanna NN**, Kosinski LA, Washington MK, Kakar S, Weiser MR, Overman MJ. [The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.](http://www.ncbi.nlm.nih.gov/pubmed/26506400) *Cancer*. 2016 Jan 15;122(2):213-21. Epub 2015 Oct 27. PMID: 26506400
68. Katz SC, Point GR, Cunetta M, Thorn M, Guha P, Espat NJ, Boutros C, **Hanna N**, Junghans RP. [Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.](http://www.ncbi.nlm.nih.gov/pubmed/27080226) *Cancer Gene Ther*. 2016 May; 23(5):142-8. Epub 2016 Apr 15. PMID: 27080226
69. Woldemichael A, Onukwugha E, Seal B, **Hanna N**, Mullins CD. [Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients.](http://www.ncbi.nlm.nih.gov/pubmed/27231791) *J Manag Care Spec Pharm.* 2016 Jun; 22(6):628-39. doi: 10.18553/jmcp.2016.22.6.628. PMID: 27231791
70. Bikov KA, Mullins CD, Hung A, Seal B, Onukwugha E, **Hanna N**. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. Oncologist. 2016 Jun;21(6):676-83. Epub 2016 Apr 28. PMID: 27125751
71. Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, **Hanna N**, Alexander HR, Hussain SP. A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2. Cancer Res. 2016 Apr 20. [Epub ahead of print] PMID: 27197190
72. Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, **Hanna N**, Alexander HR, Hussain SP. [Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.](http://www.ncbi.nlm.nih.gov/pubmed/27367029) *Oncotarget.* 2016 Jun 29. [Epub ahead of print]. PMID: 27367029
73. Wang J, Yang S, He P, Schetter A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, **Hanna N**, Alexander HR, Hussain SP. [Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/27401251) *Clin Cancer Res*.  2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.PMID: 27401251
74. Li YC, Khashab T, Terhune J, Eckert RL, **Hanna N**, Burke A, Richard Alexander H. [Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/28324285) *Ann Surg Oncol*. 2017 Aug;24(8):2259-2265. Epub 2017 Mar 21. PMID: 28324285

# [Nathenson MJ](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nathenson%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=30309356), [Barysauskas CM](https://www.ncbi.nlm.nih.gov/pubmed/?term=Barysauskas%20CM%5BAuthor%5D&cauthor=true&cauthor_uid=30309356), [Nathenson RA](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nathenson%20RA%5BAuthor%5D&cauthor=true&cauthor_uid=30309356), [Regine WF](https://www.ncbi.nlm.nih.gov/pubmed/?term=Regine%20WF%5BAuthor%5D&cauthor=true&cauthor_uid=30309356), [Hanna N](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hanna%20N%5BAuthor%5D&cauthor=true&cauthor_uid=30309356), [Sausville E](https://www.ncbi.nlm.nih.gov/pubmed/?term=Sausville%20E%5BAuthor%5D&cauthor=true&cauthor_uid=30309356). Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. [World J Surg Oncol.](https://www.ncbi.nlm.nih.gov/pubmed/30309356) 2018 Oct 11;16(1):203.

# Max Seaton, Andrew Hanna, Cherif Boutros and Nader Hanna. Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database. Ther Adv Med Oncol. 2019 May 3;11:175

# [Brigit Baglien](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor#!), [Ledibabari M.Ngaage,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor#!) [CarlyRosen,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!) [Richelle Williams,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!) [Andrea C.Bafford,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!) [Erin M.Rada,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!) [Nader N. Hanna,](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!) [Yvonne M.Rasko](https://www.sciencedirect.com/science/article/pii/S0960740418305218?dgcid=coauthor" \l "!). Outcomes of complex abdominal wall reconstruction at the time of CRS and HIPEC. Surg Oncol. 2019 Sep;30:27-32.

1. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2020 Jun;27(6):1793-1797. doi: 10.1245/s10434-020-08319-7. Epub 2020 Apr 13. PubMed PMID: 32285268.
2. The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors. Cancer. 2020 Jun 1;126(11):2566-2570. doi: 10.1002/cncr.32856. Epub 2020 Apr 13. PubMed PMID: 32282072.
3. The Chicago Consensus on peritoneal surface malignancies: Management of gastric metastases. Cancer. 2020 Jun 1;126(11):2541-2546. doi: 10.1002/cncr.32868. Epub 2020 Apr 13. PubMed PMID: 32282074.
4. The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Cancer. 2020 Jun 1;126(11):2534-2540. doi: 10.1002/cncr.32874. Epub 2020 Apr 13. PubMed PMID: 32282070.
5. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol. 2020 Jun;27(6):1761-1767. doi: 10.1245/s10434-020-08315-x. Epub 2020 Apr 13. PubMed PMID: 32285270.
6. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Ann Surg Oncol. 2020 Jun;27(6):1780-1787. doi: 10.1245/s10434-020-08322-y. Epub 2020 Apr 13. PubMed PMID: 32285271.
7. The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations. Ann Surg Oncol. 2020 Jun;27(6):1798-1804. doi: 10.1245/s10434-020-08323-x. Epub 2020 Apr 13. PubMed PMID: 32285272.
8. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. Ann Surg Oncol. 2020 Jun;27(6):1788-1792. doi: 10.1245/s10434-020-08321-z. Epub 2020 Apr 13. PubMed PMID: 32285274.
9. The Chicago Consensus on peritoneal surface malignancies: Palliative care considerations. Cancer. 2020 Jun 1;126(11):2571-2576. doi: 10.1002/cncr.32826. Epub 2020 Apr 13. PubMed PMID: 32282059.
10. The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer. 2020 Jun 1;126(11):2553-2560. doi: 10.1002/cncr.32867. Epub 2020 Apr 13. PubMed PMID: 32282068.
11. The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. Cancer. 2020 Jun 1;126(11):2525-2533. doi: 10.1002/cncr.32881. Epub 2020 Apr 13. PubMed PMID: 32282073.
12. The Chicago Consensus Guidelines for peritoneal surface malignancies: Introduction. Cancer. 2020 Jun 1;126(11):2510-2512. doi: 10.1002/cncr.32827. Epub 2020 Apr 13. PubMed PMID: 32282062.
13. The Chicago Consensus on peritoneal surface malignancies: Standards. Cancer. 2020 Jun 1;126(11):2516-2524. doi: 10.1002/cncr.32825. Epub 2020 Apr 13. PubMed PMID: 32282066.
14. The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. Cancer. 2020 Jun 1;126(11):2561-2565. doi: 10.1002/cncr.32865. Epub 2020 Apr 13. PubMed PMID: 32282069.
15. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases. Ann Surg Oncol. 2020 Jun;27(6):1768-1773. doi: 10.1245/s10434-020-08320-0. Epub 2020 Apr 13. PubMed PMID: 32285269.
16. The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer. 2020 Jun 1;126(11):2547-2552. doi: 10.1002/cncr.32870. Epub 2020 Apr 13. PubMed PMID: 32282077.
17. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2020 Jun;27(6):1774-1779. doi: 10.1245/s10434-020-08324-w. Epub 2020 Apr 13. PubMed PMID: 32285273.
18. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms. Ann Surg Oncol. 2020 Jun;27(6):1753-1760. doi: 10.1245/s10434-020-08316-w. Epub 2020 Apr 13. PubMed PMID: 32285275.
19. The Chicago Consensus Guidelines for Peritoneal Surface Malignancies: Introduction. Ann Surg Oncol. 2020 Jun;27(6):1737-1740. doi: 10.1245/s10434-020-08318-8. Epub 2020 Apr 13. PubMed PMID: 32285277.
20. The Chicago Consensus on Peritoneal Surface Malignancies: Standards. Ann Surg Oncol. 2020 Jun;27(6):1743-1752. doi: 10.1245/s10434-020-08325-9. Epub 2020 Apr 13. PubMed PMID: 32285276.
21. Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Ströbel P, Azizian A, Ried T, Gaida MM, Yfantis HG, Lee DH, Lal A, Van den Eynde BJ, Alexander HR, Ghadimi BM,**Hanna N**, Hussain SP. NO\*/RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Int J Cancer. 2020 Jun 1;146(11):3160-3169.
22. Snider JW, Molitoris J, Shyu S, Diwanji T, Rice S, Kowalski E, Decesaris C, Remick JS, Yi B, Zhang B, Hall A, **Hanna N**, Ng VY, Regine WF. Spatially Fractionated Radiotherapy (GRID) Prior to Standard Neoadjuvant Conventionally Fractionated Radiotherapy for Bulky, High-Risk Soft Tissue and Osteosarcomas: Feasibility, Safety, and Promising Pathologic Response Rates. Radiat Res. 2020 Dec 1;194(6):707-714.
23. Koroulakis A, Molitoris J, Kaiser A, **Hanna N**, Bafford A, Jiang Y, Bentzen S, Regine WF. Reirradiation for Rectal Cancer Using Pencil Beam Scanning Proton Therapy: A Single Institutional Experience. Adv Radiat Oncol. 2020 Oct 14;6(1):100595.
24. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery. Lancet. 2021 Jan 30;397(10272):387-397.

**None Peer-Reviewed Journal Articles**

A.Pinnolla, **N.Hanna**, C.Boutros. The Role of Minimally Invasive Surgery in Gallbladder Carcinoma, is it Time to Change our Approach? *Surgery Curr Res* 2015, 6:254

Chenwi Ambe, MD, Luis Gonzalez-Cuyar, M.D, Saleem Farooqui, M D, **Nader Hanna, M.D**, and Steven C. Cunningham, M.D. Ciliated Hepatic Foregut Cyst: 103 Cases in the World Literature. *OJPathology.* 2012, 2, 45-49

Cherif Boutros, **Nader Hanna**. Totally Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Mucinous Adneocarcinoma of the Appendix. *Gastroenterology*. 05/2013; DOI: 10.1016/S0016-5085(13)63902-5

Z Zheng, **N N Hanna**, E Onukwugha, K Bikov, B Seal, C D Mullins. Association between overall incremental cost and survival benefit of second line chemotherapy/biologics treatment among elderly Medicare metastatic colon cancer patients. Value in Health 05/2013; 16(3):A139.

Joseph Scalea, Brnko Bojovic, Robin Legros, Julia Choi, Andrea Herbert, **Nader Hanna**. Angiosarcoma Following Radiation Therapy for Breast Cancer: Case Presentation and Clinical Management Considerations. Open Journal of Pathology 2013 October; 03(04):180-185

C.Boutros, **N.Hanna**. Totally Laparoscopic Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy for Mucinous Adneocarcinoma of the Appendix. *Journal of Laparoendoscopic and Advanced Surgical Techniques. September 2014.*

**Books & Book Chapters**

1. Weichselbaum RR, Wayne JD, Mauceri H, Seung L**, Hanna NN**, Kharbanda S, Hallahan DE, Kufe DW. “Ionizing Radiation: A Molecular Switch for Gene Therapy.” In The Internet Book of Gene Therapy. Eds. Sobol, R.E., Scanlon, K.J., Publs. Appleton & Lange, pp 205-210, 1995
2. **Hanna NN**, Kenady DE. “Pheochromocytoma.” In Surgical Treatment Evidence-Based and Problem-Oriented. Eds. Rene G. Holzheimer, John A. Mannick. Publs. W. Zuckschwerdt Verlag, pp 498-508, 2001
3. Regine W, **Hanna NN**, Desimone P, Cohen AM. “Rectal Cancer.” In Clinical Oncology, 3rd Edition. Eds. Martin D. Abeloff, James O Armitage, John E. Niederhuber, Michael B. Kastan, W. Gillies McKenna. Publs. Churchill Livingston, May, 2004.
4. **Hanna NN**. Hereditary Diffuse Gastric Cancer Syndrome. In Encyclopedia of Diagnostic Genomic and Proteomics (Print and on line). Eds. Jurgen Fuches, Maurizio Podda. Publs. Marcel Dekker, Inc. 12/2004.
5. Pierece H, **Hanna NN**. Hereditary Breast and Ovarian Cancer Syndrome. In Encyclopedia of Diagnostic Genomic and Proteomics (Print and on line). Eds. Jurgen Fuches, Maurizio Podda. Publs. Marcel Dekker, Inc. 12/2004.
6. McKenzie S, Pierce H, **Hanna NN**. Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndrome. In Encyclopedia of Diagnostic Genomic and Proteomics (Print and on line). Eds. Jurgen Fuches, Maurizio Podda. Publs. Marcel Dekker 12/2004.
7. McKenzie S, Pierce H, **Hanna NN**. Familial Adenomatous Polyposis (FAP) Syndrome. In Encyclopedia of Diagnostic Genomic and Proteomics (Print and on line). Eds. Jurgen Fuches, Maurizio Podda. Publs. Marcel Dekker 12/2004.
8. **Hanna NN**. Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Syndromes. In Encyclopedia of Diagnostic Genomic and Proteomics (Print and on line). Eds. Jurgen Fuches, Maurizio Podda. Publs. Marcel Dekker 12/2004.
9. HR Alexander, **NN Hanna**. Isolated Hepatic Perfusion for Patients with Unresectable Hepatic Metastasis. In Regional Oncotherapies. Editor. Odysseas Zoras. Publs. Paschalidis Medical Publications 1/2007.
10. Alfred Cohen, Michael Garofalo, Philip De Simone, Nader **Hanna NN**, William Regine. “Rectal Cancer.” In Abeloff’s Clinical Oncology, 4th Edition. Eds. Martin D. Abeloff, James O Armitage, John E. Niederhuber, Michael B. Kastan, W. Gillies McKenna. Publs. Churchill Livingston, May, 2008.

#### C.Boutros, H. Sobhi, **N. Hanna**. The evolution of abdominal wall reconstruction and the role of nanobiotecnology in the development of intelligent abdominal wall prostheses**.** In Nanobiomaterials for intelligent medicaldevices. Eds. Tiwari and Kobayashi. Publs. Wiley-Scrivener; February 1, 2012.

#### Colon & Rectum. AJCC Cancer Staging Manual / Edition 8. Eds. [Stephen Edge](http://www.barnesandnoble.com/s/%22Stephen%20Edge%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Frederick L. Greene](http://www.barnesandnoble.com/s/%22Frederick%20L.%20Greene%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [David R. Byrd](http://www.barnesandnoble.com/s/%22David%20R.%20Byrd%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Robert K. Brookland](http://www.barnesandnoble.com/s/%22Robert%20K.%20Brookland%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Mary Kay Washington](http://www.barnesandnoble.com/s/%22Mary%20Kay%20Washington%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall). Publs. Springer; October 3, 2016.

#### Appendix. AJCC Cancer Staging Manual / Edition 8. Eds. [Stephen Edge](http://www.barnesandnoble.com/s/%22Stephen%20Edge%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Frederick L. Greene](http://www.barnesandnoble.com/s/%22Frederick%20L.%20Greene%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [David R. Byrd](http://www.barnesandnoble.com/s/%22David%20R.%20Byrd%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Robert K. Brookland](http://www.barnesandnoble.com/s/%22Robert%20K.%20Brookland%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall), [Mary Kay Washington](http://www.barnesandnoble.com/s/%22Mary%20Kay%20Washington%22;jsessionid=042A490B15EF8ADDA524B109AA25BB54.prodny_store01-atgap07?Ntk=P_key_Contributor_List&Ns=P_Sales_Rank&Ntx=mode+matchall). Publs. Springer; October 3, 2016.

**MAJOR INVITED SPEECHES**

International

1. Pancreatic Cancer: Advances, Controversies and Evidence-based Multimodality Therapy. 2nd World Cancer Congress, Beijing, China 6/24/2009.
2. Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intratumoral Administration of DTA-H19 in Patients with Unresectable Pancreatic Cancer. 4th World cancer Congress, Dalian, China. 5/27/2011.
3. Safety of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Older Patients. 7th International Symposium on Regional Cancer Therapies. 2/18/2012, Captiva, Florida, USA.
4. Advances in Surgical Management of Small Bowel Tumors. World Congress on Gastroenterology & Urology. 3/12/2012, Omaha, Nebraska, USA.
5. Surgical Management of Colorectal Metastasis. First conference of the Egyptian Chapter of American college of Surgeons. 9/7/12, Cairo, Egypt.
6. Evidence-Based Surgery and Outcomes for Pancreatic Cancer. First conference of the Egyptian Chapter of American college of Surgeons. 9/8/12, Cairo, Egypt.
7. Chenwi Ambe, Cherif Boutros, Daniel Zhu, **Nader Hanna**. Survival Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer. 8th International Symposium on Regional Cancer Therapies. 2/16/13, Indian Wells, CA. USA
8. New Paradigm in the Management of Rectal Cancer. Second conference of the Egyptian Chapter of American college of Surgeons. 5/25/13, Cairo, Egypt.
9. Gastric Cancer: The McDonald, the Dutch and the Magic, then What? Second conference of the Egyptian Chapter of American college of Surgeons. 5/26/13, Cairo, Egypt.
10. Comparative Effectiveness and Survival Benefit of Liver Directed Therapy, Systemic Chemotherapy and Radiation Therapy in Stage Four HCC: A SEER-Medicare Analysis. 75th Annual Surgical Update of the International College of Surgeons-US Section, June 6-8, 2013 in Jacksonville, Florida.
11. Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy; Beyond Standard of Care Treatment. The Third International Gastrointestinal Cancer Conference. December13-15, 2013. Antalya, Turkey.
12. Evidence-based Management of Colorectal Cancer Metastasis. Visiting Professor Grand Round Speaker, NCI, Cairo, Egypt. May 13, 2014.
13. Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Surface Malignancies. 3rd International Gastrointestinal and Liver Oncology Conference. May 15, 2014. Cairo, Egypt
14. Controversies in Management of Gastric Cancer. 3rd International Gastrointestinal and Liver Oncology Conference. May 15, 2014. Cairo, Egypt
15. Evidence-based Surgery for Pancreatic cancer. 3rd International Gastrointestinal and Liver Oncology Conference. May 15, 2014. Cairo, Egypt
16. Is there a Role For Cytoreductive Surgery & Hyperthermic Intraperitoneal in Colorectal cancer? Annual Meeting of the Egyptian Society of Surgical oncology. February 13, 2015. Cairo, Egypt
17. Safety and Outcomes of CRS & HIPEC in the Elderly. Peritoneal Surface Malignancy Experts Meeting. Athens, Greece May 8, 9 2015.
18. CRS & HIPEC for CRC Carcinomatosis: Improving Outcomes with Multi-Disciplinary Approach. Peritoneal Surface Malignancy Experts Meeting. Athens, Greece May 8, 9, 2015.
19. Surgical Management of Pancreatic Cancer; Predictors of outcomes. 15th Annual conference of Egyptian Society of Surgical Oncology. Cairo, Egypt 3/30/2016
20. Optimal Management of synchronous colorectal Liver Metastasis. 15th Annual conference of Egyptian Society of Surgical Oncology. Cairo, Egypt 3/30/2016
21. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer: An Experimental Therapy or Standard of Care? International Congress of Hyperthermic Oncology. New Orleans, USA 4/2016.
22. Best Evidence-Based Practice for management of CRC. Aswan cancer Institute, Egypt. Visiting Professorship. 9/26/2016
23. Breast Cancer Awareness; Myth vs Reality. Aswan cancer Institute, Egypt. Visiting Professorship. 9/26/2016
24. Evidence-Based Management of Colorectal Cancer Metastasis. University of Sohag School of Medicine. Visiting Professorship 8/1-8/4/2017
25. Evidence-Based Management of Gastric cancer. University of Sohag School of Medicine. Visiting Professorship 8/1-8/4/2017
26. Improving outcomes in pancreatic Cancer: University of Sohag School of medicine. Visiting Professorship 8/1-8/4/2017
27. Multi-Disciplinary Cancer Care in Egypt: What Should be done vs What can be done. University of Sohag School of Medicine. Visiting Professorship 8/1-8/4/2017
28. Management of Hepatic Colorectal Metastasis. Helwan University, Egypt. Visiting Professorship 11/26-11/27/2017.
29. The AJCC Staging System: What is New for GIT/Liver Malignancies. Annual International Egyptian Oncology Summit, Luxor, Egypt 11/30-12/1/2017
30. Indications & Future Opportunities for CRS & HIPEC in CRC. 18th Annual Conference, Egyptian Society of Surgical Oncology, Comprehensive Management of Peritoneal Surface Malignancy Workshop, Cairo, Egypt 411-4/13/2018
31. HIPEC in the Elderly: Is there a difference? 18th Annual Conference, Egyptian Society of Surgical Oncology, Comprehensive Management of Peritoneal Surface Malignancy Workshop, Cairo, Egypt 4/11-4/13/2018
32. Updates of Hepatic Surgery and Novel Management of HCC
33. Future Liver Remnant: Increasing the Pool for Liver Resection
34. Laparoscopic Liver Surgery. 7th International Gastrointestinal, Liver, & Uro-oncology Conference, Cairo, Egypt 5/2018
35. Indications & Future Opportunities for CRS & HIPEC in CRC. 7th International Gastrointestinal, Liver, & Uro-oncology Conference, Cairo, Egypt 5/2018
36. Multi-Disciplinary Cancer: Standard of care for Improved of Outcomes. Assuit University School of Medicine. 11/112018
37. Recent Advances in Management of Pancreatic Cancer. Assuit University School of Medicine. 11/112018

Regional/National

1. Gene Therapy for Cancer: From Bench to Bedside. Department of Surgery Grand Rounds, University of Kentucky, May 15, 1999.
2. Sphincter Sparing Surgical Options in Cancer of the Rectum. New Trends in Minimally Invasive Surgery in the Treatment of GI Cancer Seminar, University of Kentucky, November12, 1999.
3. Anatomical and Pathological Considerations for Rectal Cancer Surgery. Department of Surgery Grand Rounds, University of Kentucky, April 8, 2000.
4. Radiofrequency Thermal Ablation of Liver Tumors: A Minimally Invasive Procedure; But Is Heat Better Than Cold? GI Cancer Seminar, University of Kentucky, November 17, 2000.
5. Cancer Gene Therapy Translational Research: Where We Stand? Tumor Board, University of Kentucky, October 4, 2001.
6. “From Gene Labs to Personal Ads” Greater Kentucky Blue Grass Chapter of the Association of Clinical Research Professionals. Lexington, KY. October 4, 2002.
7. Prophylactic Surgery in Hereditary Cancer Syndromes. Department of Surgery Grand Rounds, University of Kentucky, October 23, 2002.
8. Surgical Evaluation and Management of Hepatobiliary Malignancies. The 34th Annual Medicine Review Course, University of Kentucky. November 15, 2002.
9. Surgical Evaluation and Management of Hepatobiliary Malignancies. The 34th Annual Medicine Review Course, University of Kentucky. February 21, 2003.
10. Clinical Gene Therapy for Solid Tumors. Grand Round Presentation, Department of Surgery, Baystate Medical Center, Springfield, MA. February 27, 2003.
11. Ethics and Human Research; A Clinician Prospective. University of Kentucky Clinical Research Organization. April 20, 2003.
12. Surgical Evaluation and Management of Hepatobiliary Malignancies. The 34th Annual Medicine Review Course, University of Kentucky. May 23, 2003.
13. Challenges, Controversies and Advances in Pancreatic Cancer. Special Grand Round Presentation, Department of Surgery, The Western Pennsylvania Hospital, Temple University. February 16, 2004.
14. Challenges and evidenced-based surgery for pancreatic cancer. Department of Surgery Grand Rounds, University of Kentucky, May 5, 2004
15. Surgical Evaluation and Management of Early Breast Cancer. 2nd Annual Breast Cancer Update. Baltimore, Maryland, November 19, 2004
16. Evolving Approaches in Surgical Evaluation and Management of Early Breast Cancer. 5th Annual Update in Internal Medicine, University of Maryland School of Medicine, May 23- 26, 2005.
17. Surgical Prospective in Management of Hepatic Colorectal Malignancies. Interventional Radiology Course. University of Maryland. November 7, 2006.
18. Surgical Grand Rounds: Evidence-Based DVT prophylaxis in Surgical Patients. Holy Cross Hospital. December 11, 2006
19. Anesthesia Grand Rounds: Evidence-Based DVT prophylaxis in Patients Undergoing Abdominal Surgery, Holly Cross Hospital. March 12, 2007
20. Appropriate DVT Prophylaxis for at Risk Patients. Surgical Grand Rounds. St. Vincent Hospital. Green Bay, Wisconsin. March 28, 2007
21. GYN Grand Rounds: VTE Prophylaxis and Best Practice Measures in Patients Undergoing Abdominal Surgery. University of Tennessee, Knoxville, TN. 4/13/07
22. Pancreatic Cancer: Challenges and Evidence-Based Surgery. Surgery Grand Rounds, Pinnacle Health System/Harrisburg Hospital, Harrisburg, PA 4/26/2007
23. Surgery Grand Rounds: Appropriate VTE prophylaxis in Surgical Patients. Northwest Hospital Center, Randallstown, MD May 2, 2007
24. Surgical Evaluation and Management of Hepatobiliary malignancies. Grand Rounds. Montgomery General Hospital, September 13, 2007
25. Surgical Management of Extremity Sarcoma. Grand Rounds. Providence Hospital, Washington, DC. December 6, 2007
26. Optimal Management of Hepatic Colorectal Metastases. 1st Annual GI Cancer Symposium. April 2009
27. Cytoreductive Surgery and HIPEC: Post-operative Management. First workshop for Department of Defense Surgical Oncologist. Baltimore, MD June 1, 2009.
28. Surgical Advances & Techniques in GI Malignancies. 2nd Annual GI Cancer Symposium. Baltimore, MD. 4/30/10.
29. Surgical Perspectives in Management of CRC Hepatic Metastases. Grand Rounds Presentation, Laurel regional Hospital, laurel, Maryland. 6/17/10.
30. Pancreatic Cancer: “Classic and Emergent Treatments”. 4th Annual Symposium on Pancreatic Cancer, New York City, NY. 1/28/2011.
31. Surgery for Colorectal cancer: Current Evidence-Based Practice and Emerging Techniques. 3rd Annual GI Cancer Symposium, Baltimore, Maryland. 4/8/2011.
32. VTE Prophylaxis in Patients Undergoing Abdominal Surgery. Grand Rounds, Chester River Hospital, Chester Town, Maryland. 9/28/2011.
33. Surgery Update for hepatic CRC Metastasis. Society of Interventional Radiology Foundation’s Research Consensus Panel (RCP) on the Management of Metastatic Colorectal Cancer. Washington DC. 10/3/2011.
34. Metastatectomy: A Necessary Evil or Not. Department of Surgery Grand Rounds, UMDNJ-SOM, 12/5/2011.
35. Introduction to Surgical palliation. Palliative Care: An Interdisciplinary Symposium, New York City, NY. 12/9/2011.
36. Management of peritoneal Metastases from Colon Cancer: This is How I Do It. Workshop on The Management of Peritoneal Metastases. MedStar Washington Hospital center, Washington, DC. June 21-22, 2012.
37. Gastric Cancer: Beyond the McDonald, the Dutch and the Magic. 4th annual GI Cancer Symposium, June 7, 2013, Baltimore, MD.
38. Gastric Cancer: Can HIPEC Improve Outcomes. Surgical Oncology at Mercy Conference “Peritoneal Dissemination of Cancer: Present Treatment, Guidelines and Controversies”, June 20-21, 2013. Baltimore, MD.
39. M & M in Gastric Cancer; Tough to Digest or Food for Thought. Visiting Professor Grand Round speaker. Weill Cornell Medical College. October 28, 2013, New York.
40. Gastric Cancer: Beyond the Dutch, the McDonald and the Magic Trials. Grand Round Presentation, St. Joseph Medical Center, Baltimore, MD. January 17, 2014
41. Lessons learned in CRS and HIPEC in Colorectal cancer patients. The 3rd Annual Update and Workshop on Management of Peritoneal Surface Malignancies. June 12, 2014, Baltimore, MD.
42. The Whipple Procedure Made Simple. Department of Surgery Grand Rounds, UMDNJ-SOM, 9/11/2014.
43. Evidence-based Management of Gastric Cancer. Grand Rounds Presentation, Holy Cross Hospital, Silver Spring, MD 9/16/14
44. Colorectal Cancer Management: Evidence-Based Practice. Grand Rounds Presentation, St. Joseph Medical center, Baltimore, MD. 9/19/14
45. Quality Initiatives in the UM Cancer Network. 8th Annual Cancer Symposium, University of Maryland St. Joseph Medical Center Cancer Institute. 11/4/2014
46. Colorectal Cancer Management: Evidence-based practice. Grand Rounds, Shady Groove Hospital. April 16, 2015
47. Update of CRS with HIPEC for Gastric cancer**.** The 4th Annual Mid-Atlantic Peritoneal Malignancy Workshop. June 11, 12 2015, Virginia Beach, VA.
48. Improving Outcomes in Pancreatic Cancer. 3rd NCI-Pancreatic cancer symposium. September 28, 29. 2015, NCI, Bethesda, MD.
49. Recent Advances in Management of GI Cancers. Grand Rounds Speaker, Prince George’s Hospital Center. 1/20/2016.
50. Neoadjuvant vs Adjuvant Therapy; A New Paradigm Shift in Management of PDAC. 4th NCI-Pancreatic cancer symposium. September 8, 9. 2016, NCI, Bethesda, MD.
51. Evidence-based Management of Gastric Cancer. Grand Rounds Presentation, Washington Hospital Center, Washington, D.C. 1/17/2017.
52. Cystic Neoplasms of the Pancreas: Path Moving Forward. 5th NCI-Pancreatic cancer symposium. October 2-3, 2018, NCI, Bethesda, MD.

Local

1. Pancreatic cancer: Challenges and critical analysis of surgical techniques, Department of Surgery Grand Rounds, University of Maryland, November 4, 2004
2. Surgical dilemma in GI cancer. Division of Gastroenterology Grand Rounds, University of Maryland, December 15, 2004
3. Genetics of Colorectal Cancer. Genetic Counseling graduate students, University of Maryland, March 2005.
4. Introduction to genetics of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 30, 2006
5. Colorectal Cancer. Guest speaker, Maryland Public TV. April 18, 2006.
6. Surgical Management of Extremity Soft Tissue Sarcoma. Radiation Oncology Resident Lecture Series 4/19/2006.
7. Treatment Success in Cancer. Epidemiology course for undergraduate students, School of Epidemiology and Public Health, University of Maryland. 5/10/2006
8. Prophylactic Cancer Surgery: Indications and Recommendations. Department of Surgery Grand Rounds, University of Maryland, June 15, 2006.
9. Surgical Management of Rectal Cancer. Medical Oncology Fellows Lecture Series 10/13/2006.
10. Pancreatic Cancer; Evidence-based Practice. Medical Oncology Fellows Lecture Series 10/27/2006.
11. Surgery Residency Journal Club: Colorectal Cancer. November 9, 2006.
12. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 29, 2007
13. Soft Tissue Sarcoma; Surgical Prospective. Medical Oncology Fellows Lecture Series 3/29/2007.
14. Evidence-based Surgery and controversies in rectal cancer. Department of Surgery Grand Rounds, University of Maryland, September 13, 2007.
15. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling undergraduate students, University of Maryland, March 29, 2008
16. Rectal Cancer: Surgical Prospective. Radiation Oncology lecture Series 12/3/08
17. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 25, 2009
18. Metastatectomy: A Necessary Evil or Not. Department of Surgery Grand Rounds, University of Maryland, June 4, 2009.
19. Sarcoma: Multidisciplinary approach. Radiation Oncology Resident Lecture Series 6/10/2009.
20. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 25, 2010.
21. Evidence-Based Surgery and Controversies in management of Gastric Cancer. Surgical Grand Round Speaker, Dept of Surgery, University of Maryland School of Medicine 4/29/10
22. Metastasectomies: Do They Really Work? Hematology Oncology. Grand Rounds Speaker, University of Maryland School of Medicine 5/3/10.
23. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 2011.
24. Palliative Surgical Oncology. Palliative care lecture series to surgical residents, University of Maryland 8/12/2010.
25. Malignant Diseases of the Liver. Third year students clerkship lecture series, University of Maryland 9/9/2010.
26. Pain Control in Cancer Patients. Palliative care lecture series to surgical residents, University of Maryland 9/16/2010.
27. Cancer and Sexuality. Palliative care lecture series to surgical residents, University of Maryland 10/21/2010.
28. Colon and Rectal cancer. Third year student clerkship lecture series, University of Maryland 12/2/2010.
29. Controlling nausea/Vomiting in Cancer Patients. Palliative care lecture series to surgical residents, University of Maryland 12/09/2010.
30. Malignant Diseases of the Liver. Third year student clerkship lecture series, University of Maryland 12/10/2010.
31. Symptom Clusters in Patients with Advanced Cancer: Cachexia, Anorexia & Asthenia. Palliative care lecture series to surgical residents, University of Maryland 3/17/2010.
32. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 24, 2011.
33. Rectal Tumors: How to Manage. Surgical Grand Rounds, University of Maryland, Baltimore, MD. 5/19/2011.
34. Gastric Cancer, Evidence-Based Practice. Surgery Resident Lecture series, University of Maryland, Baltimore, MD. 5/19/2011.
35. Overview of colorectal cancer. Clinical Cancer Genetics course for genetic counseling graduate students, University of Maryland, March 24, 2011.
36. Open Mic Night, Ask the Cancer Experts Cancer Seminars: Belly Cancers, Columbia, MD 4/25/2012
37. Soft Tissue sarcoma: Pitfalls in Diagnosis & Management and Recent Advances in Treatment Surgical Grand Rounds, University of Maryland, Baltimore, MD. 1/17/2013.
38. ACS NSQIP: Opportunity For Career Development and Improving Personal Outcomes. University of Maryland Research Retreat January 11, 2014.
39. Biliary neoplasms. Surgery Resident Lecture series, University of Maryland, Baltimore, MD. 9/21/2017.
40. Malignant Small Bowel Tumors. Surgery Resident Lecture series, University of Maryland, Baltimore, MD. 12/20/2018.
41. Gastric cancer; Challenges, Controversies and Advances. Surgical Grand Rounds, University of Maryland, Baltimore, MD. 1/10/2019.